Building the representation of a new innovation center e science of avant -garde at Amgen's global headquarters in Thousand Oaks, California.
Courtesy: Amgen
Amgen On Tuesday, he said that he will spend more than $ 600 million to build a new research and development installation at its headquarters in Thousand Oaks, California, the last of a series of new investments in the United States by the pharmaceutical industry.
Drug manufacturers have been fighting to boost their presence in the United States, since President Donald Trump threatens to tighten the industry with tariffs on pharmaceutical products imported to the country. Trump has said that these levies will encourage companies to return to production at a time when the manufacture of national drugs has been drastically reduced in the last decade.
In a statement, Amgen said that the construction of the installation will begin in the third quarter of this year and create hundreds of jobs in the United States.
In particular, the installation is not a manufacturing plant, but it will allow researchers, engineers and scientists to collaborate in finding next -generation medications for patients with “more serious diseases,” according to the company. Amgen said the building has “advanced automation and digital capabilities”, which will provide scientists with the necessary tools for that research and development.
“In Amgen, we continue to invest in the future of American science and innovation,” said CEO Bob Bradway in the statement. “The center will train our scientists with the tools and the collaborative environment they need to shape the next era of scientific discovery and advance medications that improve human health.”
Amgen said that since the approval of the 2017 tax and job cuts law, it has invested almost $ 5 billion in direct US capital expenses. In April, the company announced an expansion of $ 900 million of its biotechnology manufacturing facilities of Ohio. In December, the drug manufacturer announced that it would spend $ 1 billion to build a second plant of drug substances in Holly Springs, North Carolina.
These investments are produced after the US Food and Medicines Administration. In August they launched a program that aims to facilitate that companies establish new medication manufacturing plants in the US. UU. It estimates that the White House estimates that it can currently take five to 10 years to build a new manufacturing capacity for pharmaceutical products, which previously called “unacceptable from a national point of view.”
